×
About 2,060 results

ALLMedicine™ Hypogammaglobulinemia Center

Research & Reviews  672 results

B-cell cancers: Sparse insight into preventing infections
https://www.mdedge.com/hematology-oncology/article/262059/cll/b-cell-cancers-sparse-insight-preventing-infections
Randy Dotinga

Mar 28th, 2023 - Cases of acquired hypogammaglobulinemia are expected to rise, as patients live longer with such B-cell malignancies as chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, and multiple myeloma. But there’s a striking shortage of research into.

Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric s...
https://doi.org/10.1007/s10067-023-06559-y
Clinical Rheumatology; Modica RF, Thatayatikom A et. al.

Mar 28th, 2023 - Childhood-onset neuropsychiatric systemic lupus erythematosus (cNPSLE) with psychosis is a challenging manifestation of SLE. Pathogenic long-lived plasma cells (LLPCs) are not specifically targeted by standard immunosuppression and their persisten...

COVID-19 disease frequency, risk factors, and re-infection rates in patients with autoi...
https://doi.org/10.1111/1756-185X.14676
International Journal of Rheumatic Diseases; Armağan B, Konak HE et. al.

Mar 22nd, 2023 - Rituximab, which is used in autoimmune rheumatic diseases (ARD), can cause both an increased risk of development of COVID-19 disease and re-infection due to its potent and long-acting immunosuppression. So, we aimed to evaluate the frequency, risk...

Pediatric Bronchitis Treatment & Management
https://emedicine.medscape.com/article/1001332-treatment

Mar 20th, 2023 - Approach Considerations Emergency care for acute bronchitis or exacerbation of chronic bronchitis must focus on ensuring that the child has adequate oxygenation and hydration. Outpatient care is appropriate unless bronchitis is complicated by seve...

Pediatric Bronchitis Clinical Presentation
https://emedicine.medscape.com/article/1001332-clinical

Mar 20th, 2023 - History Acute bronchitis begins as a respiratory tract infection that manifests as the common cold. Symptoms often include coryza, malaise, chills, slight fever, sore throat, and back and muscle pain. The cough in these children is usually accompa...

see more →

Drugs  11 results see all →

Clinicaltrials.gov  44 results

Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT04805203

Mar 2nd, 2023 - MM is a hematological malignancy, supposed mainly not curable, except for some exceptional patients, despite the availability of numerous new drugs. The patients are highly susceptible to infections, both bacterial and viral, due to a defect immun...

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
https://clinicaltrials.gov/ct2/show/NCT04499573

Feb 22nd, 2023 - The main objectives of the study are: To investigate the incidence of adverse events of grade 3-5 within after CD19/CD22 CAR lymphocyte infusion by day 28, To evaluate the incidence of complete remission and MRD-negative CR by day 28 To evaluate t...

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
https://clinicaltrials.gov/ct2/show/NCT02579967

Feb 17th, 2023 - Background: Primary immunodeficiency diseases (PIDs) are conditions associated with major quantitative or qualitative immunologic abnormalities that are, in most cases, due to defects in cells of hematopoietic origin Participants with PID can have...

Genetic Studies of Chronic Active Epstein-Barr Disease
https://clinicaltrials.gov/ct2/show/NCT00032513

Feb 8th, 2023 - Patients with chronic active Epstein-Barr virus (CAEBV) have (a) an illness that began as a primary infection with EBV or markedly elevated titers of antibodies to EBV, (b) histological evidence of organ disease, and (c) elevated EBV DNA levels in...

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
https://clinicaltrials.gov/ct2/show/NCT00967785

Feb 8th, 2023 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...

see more →

News  97 results

B-cell cancers: Sparse insight into preventing infections
https://www.mdedge.com/hematology-oncology/article/262059/cll/b-cell-cancers-sparse-insight-preventing-infections
Randy Dotinga

Mar 28th, 2023 - Cases of acquired hypogammaglobulinemia are expected to rise, as patients live longer with such B-cell malignancies as chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, and multiple myeloma. But there’s a striking shortage of research into.

Treatments Branch Out in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/treatments-branch-out-in-newly-diagnosed-and-relapsed-refractory-multiple-myeloma

Nov 17th, 2022 - Therapeutic strategies such as defining the optimal timing of autologous stem cell transplant (ASCT), implementing CAR T-cell agents, and introducing BCMA-directed bispecific antibodies are building on current standards of care (SOCs) in multiple ...

Addressing Adverse Events With Bispecific Antibodies with Focus on CRS Management
https://www.onclive.com/view/addressing-adverse-events-with-bispecific-antibodies-with-focus-on-crs-management

Oct 11th, 2022 - Transcript: Ajai Chari, MD:But putting that aside, let’s talk a little bit about adverse effects, too. Does anybody want to start with the adverse effects of BCMA [B-cell maturation antigen] as a class? And also distinguishing if you think there ...

Bispecific Antibody ABBV-383 Looks to Fill Unmet Need in Heavily Pretreated Multiple Myeloma
https://www.onclive.com/view/bispecific-antibody-abbv-383-looks-to-fill-unmet-need-in-heavily-pretreated-multiple-myeloma

Aug 28th, 2022 - Promising safety and efficacy results were observed with the novel bispecific antibody ABBV-383 in patients with heavily pretreated relapsed or refractory multiple myeloma, according to updated results from a phase 1 trial (NCT03933735) presented ...

Individualized Care Drives Treatment Focus in AML, DLBCL, and CLL
https://www.onclive.com/view/individualized-care-drives-treatment-focus-in-aml-dlbcl-and-cll

Jul 11th, 2022 - Future advances in leukemia and lymphoma treatment will arise from careful consideration of current management strategies, explained Ehab Atallah, MD, who emphasized the importance of framing future directions around present unmet needs, such as r...

see more →